This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ophthalmological Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Eyal Banin, MD, PhD; Ruth S. Shalev, MD; Alexey Obolensky, MD, PhD; Ruhama Neis; Itay Chowers, MD; Varda Gross-Tsur, MD

Arch Ophthalmol. 2003;121:811-816.

Objective  To evaluate central and peripheral retinal function in patients treated with vigabatrin, an antiepileptic drug associated with peripheral visual field constriction (VFC).

Methods  Six patients with epilepsy treated with vigabatrin as add-on therapy for at least 3 years were included in this observational case series. All patients underwent a clinical ophthalmologic examination, color vision testing, standard perimetry, and full-field and focal foveal cone electroretinography. Four patients, 3 of whom had VFC, completed specialized computerized static light- and dark-adapted perimetry.

Results  In 9 of 11 eyes tested, foveal cone electroretinographic amplitudes were at or below the lower limit of normal. Dark-adapted perimetry demonstrated abnormal rod-derived visual fields in the 3 patients with vigabatrin-attributed VFC, whereas rod-derived thresholds were within normal limits throughout the visual field in the patient who did not have VFC.

Conclusions  Our results suggest that vigabatrin not only impairs peripheral cone-derived function as manifested by VFC but also affects foveal cone electroretinographic amplitudes and rod-derived visual fields. The clinical dilemma regarding the use of vigabatrin therapy is further complicated since central as well as peripheral visual function seems to be adversely affected.

From the Department of Ophthalmology, Hadassah-Hebrew University Hospital (Drs Banin, Obolensky, and Chowers, and Ms Neis), and the Neuropediatric Unit, Shaare Zedek Medical Center (Drs Shalev and Gross-Tsur), Jerusalem, Israel. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Common Founder Mutation of CERKL Underlies Autosomal Recessive Retinal Degeneration with Early Macular Involvement among Yemenite Jews
Auslender et al.
IOVS 2007;48:5431-5438.
ABSTRACT | FULL TEXT  

Homozygosity for a Novel ABCA4 Founder Splicing Mutation Is Associated with Progressive and Severe Stargardt-like Disease
Beit-Ya'acov et al.
IOVS 2007;48:4308-4314.
ABSTRACT | FULL TEXT  

Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
Werth and Schadler
IOVS 2006;47:3028-3035.
ABSTRACT | FULL TEXT